Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term monthly oral ibandronate (100 mg vs 150 mg) in women with postmenopausal osteoporosis
2004-001548-60Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibandronic acid in postmenopausal osteoporosis (2 arms), sponsored by Roche. Primary endpoint: Lumbar spine (L2–L4) bone mineral density. Started Aug 2004; status: completed.
02
Drugs
ibandronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2004-001548-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001548-60.